RNAm expression profile of cancer marker genes in HepG2 cells treated with different concentrations of a new indolin-3-one from Pseudomonas aeruginosa.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
12 authors.
Lucas Milanez BenicioDepartment of General Biology, State University of Londrina, Londrina, PR, Brazil.ORCID 0000-0002-2843-1975
Ane Stefano SimionatoMicrobial Ecology Laboratory, Department of Microbiology, State University of Londrina, Londrina, PR, Brazil.ORCID 0000-0003-4158-6151
Cláudio Roberto NovelloChemistry and Biology Academic Department, Federal University of Technology-Paraná, Francisco Beltrão, PR, Brazil.
Jeconias Rocha GuimarãesPhysics and Mathematics Academic Department, Federal University of Technology-Paraná, Francisco Beltrão, PR, Brazil.
Ingrid FelicidadeLaboratory of Toxicological Genetics, Department of General Biology, State University of Londrina, Londrina, PR, Brazil.
Admilton Gonçalves de OliveiraMicrobial Ecology Laboratory, Department of Microbiology, State University of Londrina, Londrina, PR, Brazil.ORCID 0000-0003-1556-5146
João Carlos Palazzo de MelloPharmaceutical Biology Laboratory, Palafito, State University of Maringá, Maringá, BR- 87020-900, Brazil.
Mário Sérgio MantovaniLaboratory of Toxicological Genetics, Department of General Biology, State University of Londrina, Londrina, PR, Brazil.
Andreas Lazaros ChryssafidisLaboratory of Veterinary Toxicology, Department of Preventive Veterinary Medicine, State University of Londrina, Londrina, PR, Brazil.
Galdino AndradeMicrobial Ecology Laboratory, Department of Microbiology, State University of Londrina, Londrina, PR, Brazil. gal.andrade7@gmail.com.ORCID 0000-0002-3238-2555
Ilce Mara de Syllos ColusDepartment of General Biology, State University of Londrina, Londrina, PR, Brazil.ORCID 0000-0001-9098-1698
Marcelo Tempesta de OliveiraLaboratory of Toxicological Genetics, Department of General Biology, State University of Londrina, Londrina, PR, Brazil.
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
The present study tested the effects of a newly identified indolin-3-one compound (compound 1), produced by Pseudomonas aeruginosa, on HepG2 cells. The MTT assays demonstrated decreased metabolic activities in HepG2 cells treated with compound 1, with dose- and time-dependent intensifying effect, starting at a concentration of 40 µM. The IC
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
RNAm expression profile of cancer marker genes in HepG2 cells treated with different concentrations of a new indolin-3-one from Pseudomonas aeruginosa. · full record | OpenQuestion